^
Association details:
| Biomarker: | IDH2 mutation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug Class: | IDH1 inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
IDH inhibitors or chemotherapy in relapsed or refractory IDHmut acute myeloid leukemia.
Published date:
05/25/2023
Excerpt:
We identified 74 patients with IDH1mut or IDH2mut mutated AML….These were grouped into three salvage cohorts: IDH inhibitors with or without a hypomethylating agent (HMA) (N = 3), intensive fludarabine-based salvage (FLAG) (N = 9), and venetoclax + HMA (N = 7)....Overall survival significantly favored the IDH inhibitor cohort (p = 0.030)....Despite patients in the IDH inhibitor cohort being significantly older, the use of IDH inhibitors, with or without a hypomethylating agent, in the second line following the failure of intensive chemotherapy was associated with significantly superior overall survival...
DOI:
10.1200/JCO.2023.41.16_suppl.e19043
